A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

ClinicalTrials.gov ID: NCT00077623

Public ClinicalTrials.gov record NCT00077623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.

Study identification

NCT ID: NCT00077623
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 572 participants

Conditions and interventions

Conditions

Anemia

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2004 (Type not available)
Primary completion: Sep 2005 (Actual)
Completion: Sep 2005 (Actual)
Last update posted: May 25, 2016

2004 – 2005

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Hot Springs	Arkansas	71901	—
Not listed	Los Angeles	California	90033	—
Not listed	Riverside	California	92501	—
Not listed	Sacramento	California	95816-5119	—
Not listed	San Jose	California	95116-1906	—
Not listed	Boston	Massachusetts	02130	—
Not listed	Springfield	Massachusetts	01107	—
Not listed	Detroit	Michigan	48202-2689	—
Not listed	Brooklyn Center	Minnesota	55430	—
Not listed	Raleigh	North Carolina	27609	—
Not listed	Winston-Salem	North Carolina	27157-1023	—
Not listed	Toledo	Ohio	43606	—
Not listed	Portland	Oregon	97210	—
Not listed	Dallas	Texas	75216	—
Not listed	Houston	Texas	77030	—
Not listed	San Antonio	Texas	78229	—
Not listed	Morgantown	West Virginia	26506	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00077623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 25, 2016 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00077623 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →